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Regeneration of Human Dermis by a Multi-Headed
Peptide
Joan Attia-Vigneau1, Christine Terryn2, Sandrine Lorimier3, Jerome Sandre4, Frank Antonicelli3,5 and
William Hornebeck3,5
Skin aging is characterized by deterioration of the dermal collagen fiber network due to both decreased collagen
expression and increased collagenolytic activity. We designed and evaluated in vitro and ex vivo the efficacy of a
trifunctional peptide (TFP) to restore collagen and elastin fibers. TFP was constituted of an elastokine motif
(VGVAPG)3, able to increase matrix constituent expression through the stimulation of the elastin-binding protein
receptor, a GIL tripeptide occupying matrix metalloproteinase-1 subsites, and a RVRL linker domain acting as a
competitive substrate for urokinase. The effects of TFP on type I, type III collagens, and elastin expression in
dermal fibroblasts were determined by quantitative real-time reverse-transcriptase–PCR and western blotting.
TFP’s inhibitory capacity against MMP-1, plasmin, and urokinase was assessed using synthetic substrates,
immunohistochemistry, and skin tissue sections as natural substrates. A skin explant model was used to
recapitulate aging-induced dermal changes along culture extent. Collagen and elastin fiber structure was
analyzed by two-photon fluorescence, second harmonic generation, and confocal microscopies. Compared with
the different sections constituting the full peptide, we found that TFP activated the production of matrix
constituents while inhibiting MMP-1 in vitro and ex vivo. It also induced a proper fiber network organization,
reflecting the potency of TFP in skin remodeling and regeneration.
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INTRODUCTION
During skin’s chronological aging, the vasculature atrophies
and the supporting dermis deteriorate with networks of
collagens and elastin becoming disorganized (Farage et al.,
2009; Naylor et al., 2011; Robert et al., 2012). Vascular
disorders associated with such matrix deterioration might
increase the susceptibility of the elderly to stasis dermatitis
or pressure ulcers (Farage et al., 2009). The important half-life
of collagen and elastin exposes these networks (Mecham,
1991) to slow accumulated damage, which interferes with
the tissue’s rheological properties, but also modifies fibro-
blast phenotype (Varani et al., 2006). Fragmentation of
dermal collagen with age has been attributed to matrix
metalloproteinase-1 (MMP-1), which cleaves several collagen
types with the highest affinity for type III collagen (Fligiel et al.,
2003; Pardo and Selman, 2005). Additionally, MMP-1 can
activate cytokines such as IL-1b and tumor necrosis factor-a,
known as MMP inducers in fibroblasts (Dasu et al., 2003).
Also, reduced mechanical tension, as generated by collage-
nolysis, was shown to decrease collagen production while
increasing reactive oxygen species-dependent MMP-1 expres-
sion (Fisher et al., 2009). Accordingly, MMP-1 expression is
enhanced either in dermal fibroblasts from aged individuals or
following fibroblast senescence induced by replication or
oxidative stress (Bizot-Foulon et al., 1995; Zaw et al., 2006).
Collectively, reduced collagen production in chronologically
aged skin, attributed to fibroblast aging and decreased level of
mechanical stimulation (Lambert et al., 1992; Fisher et al.,
2009), combined with increased matrix degradation and
disorganization, reduces the physiological skin properties
and may lead to increased susceptibility to pathologies.
In keeping with such anabolic–catabolic interplay, an ideal
skin remodeling and regenerative agent should increase
collagen synthesis while interfering with MMP activity. Matri-
kines, as bioactive fragments from matrix proteins, have been
proposed as tissue regenerative agents (Cauchard et al., 2004;
Tran et al., 2005). Among matrikines, elastokines, defined
as peptides with an xGxxPG consensus sequence, are
probably one of the most promising skin regenerative agents.
They were described to stimulate fibroblast proliferation
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(Kamoun et al., 1995) and matrix production (Hinek et al.,
2005), as well as to impede ceramide-induced apoptosis
(Cantarelli et al., 2009). Besides, elastokines were found to
be potent proangiogenic compounds as VEGF (Robinet et al.,
2005). All these properties have been attributed to elastokine’s
interaction with a cell membrane-associated protein identified
as a spliced form of b-galactosidase (S-Gal), acting as a
receptor when associated to Neuraminidase-1 and to pro-
tective protein/cathepsin A (Antonicelli et al., 2007, 2009).
However, S-Gal occupancy by elastokines was shown to
initiate MMP-1 gene transcription in fibroblasts (Brassart
et al., 2001). Therefore, those elastin peptides could simu-
ltaneously stimulate collagen deposition and collagenolysis,
showing both beneficial and adverse effects. With the aim of
obtaining an elastokine with a strong regenerative power,
while eliminating adverse effects, the sequence (Val-Gly-Val-
Ala-Pro-Gly)3 was coupled to the tripeptide GIL (Gly-Ile-Leu)
designed to inhibit MMP-1. A peptide linker RVRL (Arg-Val-
Arg-Leu) was introduced between these entities, which could
recognize proteases of the plasminogen system. The potential
of this trifunctional peptide (TFP) to stimulate the expression of
collagen(s) as well as elastin constituents, and to downregulate
collagenase expression and activity, was evaluated in vitro
using dermal skin fibroblasts, and ex vivo using a skin explant
model.
RESULTS
In vitro influence of TFP on type I and III collagen, tropoelastin,
MMP-1, and MMP-3 expression by human dermal fibroblasts
(HDFs)
The ability of the different peptides to modulate matrix
constituents and MMP expression was evaluated by quantita-
tive real-time reverse-transcriptase–PCR. HDFs were treated
for 24 hours with 100mg ml 1 of peptides (P1–P5), and
COL1A1, COL3A1, ELASTIN, MMP-1, and MMP-3 messenger
RNA (mRNA) levels were determined (Figure 1a). For matrix
constituents, P1, i.e., TFP, P2, and P3, three peptides with
the (VGVAPG)3 motif, significantly enhanced type I collagen
and elastin expression (about 1.5–2 fold, Po0.001). Type III
collagen expression was markedly increased by those three
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Figure 1. Variations in type I, type III collagen, elastin, matrix metalloproteinase (MMP)-1, and MMP-3 messenger RNA (mRNA) and protein expressions by
peptides (P1–P5). (a) Human dermal fibroblasts (HDFs) were treated by peptides (100mg ml 1) for 24 hours. Total RNA was isolated and mRNA levels were
quantified by real-time reverse transcriptase–PCR. Results are shown as histograms of relative mRNA expression: COL1A1 (&), COL3A1 (’), ELASTIN ( ),
MMP-1 ( ), and MMP-3 ( ) versus glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and SD corresponding to the three experiments. (b) The HDFs were
cultured as in (a). Collagen (Col)1 (&), Col3 (’), Elastin ( ), MMP-1( ), and MMP-3 ( ) expressions were analyzed by western blot and quantified by
densitometry. Histograms represent the mean of values relative to control (Ctrl; without peptide) and SD of three independent experiments with similar results.
***Pp0.001; **Pp0.01; *Pp0.5 versus controls. b-Act, b-actin.
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peptides, with an optimum effect (3.5-fold, Po0.001)
observed with the full-length peptide (P1). The highly signi-
ficant effect of elastokine-containing peptides on type III
collagen expression was confirmed by western blotting
(Figure 1b). Conversely, both control peptides, not containing
the elastokine repeats (P4 and P5), did not demonstrate any
effect on the expression of those genes. All P1’s stimulatory
effects on collagen expression could be suppressed by lactose
(2 mM), deltas of 73% for type I collagen and 89% for type III
collagen, indicating S-Gal involvement (Figure 2a). Regarding
MMPs, P1, P2, P3, and P4 weakly but significantly enhanced
MMP-1 and MMP-3 mRNA expression (about 1.2–1.5-fold,
Po0.01), whereas P5 had no effect (Figure 1a). These slight
variations were not confirmed by western blotting (Figure 1b).
A deeper investigation of the mechanisms involved
in P1-induced matrix components showed that P1 increased
ERK (32%) and AKT (139%) phosphorylation after 30-min
stimulation (Figure 2b). The inhibition of MEK with U0126
(10mM) and of PI3K with LY294002 (20mM) blocked the
phosphorylation induced by P1 treatment.
In vitro and ex vivo influence of TFP on MMP-1 activity and
proteases of plasminogen system
The three peptides containing the GIL domain (P1, P4 and P5)
inhibited MMP-1 activity in a time- and concentration-dependent
manner, with an IC50 (peptide concentration leading to 50%
of enzyme inhibition) equal to 4.4105, 4105 and
6105 M, respectively (Figure 3a). To further demonstrate
the anti-collagenolytic activity of P1, collagen degradation
was monitored by confocal microscopy and immuno-
histochemistry on skin tissue sections incubated with MMP-1
(Figure 3b). Deposition of active MMP-1 (80 ng ml1, 4 hours)
onto skin sections decreased the extent of type I and type III
collagen immunolabeling by 43% (Po0.001) and 36.5%
(Po0.001), respectively. Co-incubation with P1 (100mg ml1)
reduced the MMP-1-induced type I and type III collagen
degradation by 33.5% (Po0.001) and 17.6% (Po0.01),
respectively. Besides, P1 also suppressed urokinase plasmino-
gen activator (uPA) activity in a time- and concentration-
dependent manner, with an IC50 of 8.3.10
6
M when used
at a concentration of 105 M (Figure 3c). Conversely, P1 did
not exhibit any inhibitory activity on plasmin amidolytic
activity.
Ex vivo influence of TFP on dermal regeneration
In the absence of treatment, expressions of type I and type III
collagens, elastin, and MMP-1 determined at days 0, 6, and 12
in human skin explants cultured, measured both at the mRNA
level by quantitative real-time reverse-transcriptase–PCR and
at the protein level by immunohistochemistry and confocal
microscopy, revealed that type I collagen, type III collagen,
and elastin expression levels progressively dropped with time
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Figure 2. Peptide 1 (P1) stimulates collagen expressions throughout the elastin-binding protein receptor and phosphorylation of ERK and AKT. (a) Human
dermal fibroblasts (HDFs) were treated with peptide 1 (P1; 100mg ml 1) for 24 hours and elastin-binding protein antagonist (2 mM lactose (Lac)) was added,
or not, 1 hour before stimulation. Collagen (Col)1 (&) and Col3 (’) expressions were analyzed by western blot and quantified by densitometry. Histograms
represent the mean of values relative to control (Ctrl; without peptide) and SD of three independent experiments with similar results. ***Pp0.001; **Pp0.01;
*Pp0.5 versus controls. (b) HDFs were treated with P1 (100mg ml1) for 30 minutes. The mitogen-activated protein kinase/ERK kinase (10mM U0126) and
phosphatidylinositol 3-kinase (20mM LY294002 (LY)) inhibitors were added (þ ), or not ( ), 1 hour before stimulation. P-ERK/ERK and P-AKT/AKT expression
levels were analyzed by western blot. b-Act, b-actin.
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of culture (Figure 3a and b). At day 12, levels of type I
collagen, type III collagen, and elastin were reduced by 40%,
64%, and 55%, respectively, compared with day 0. Conver-
sely, MMP-1 expression increased during this period of time,
with the highest expression (50-fold) at day 12 of culture
(Figure 3c).
In the presence of P1 (100mg ml1), the above-observed
decreased expressions of COL1A1, COL3A1, and ELASTIN
mRNA levels were abolished at day 6 (Figure 4a). Expression
of COL3A1 was even enhanced. Identical effects were
obtained on matrix protein expression by immunohistochem-
istry and confocal microscopy (Figure 4b): type I collagen,
type III collagen, and elastin protein expression levels were
enhanced by 20%, 150%, and 60%, respectively. At day 12,
COL1A1, COL3A1, and ELASTIN mRNA expression levels
were similar to their respective values determined at day 0
(Figure 4a). Whatever the period of time, MMP-1 mRNA
expression was not affected by the presence of P1 and still
remained at the level observed at day 0. Similar effects of P1
were obtained at the protein level as determined by morpho-
metric analysis (Figure 4b): levels of type I collagen, type III
collagen, and elastin were back to baseline when observed at
day 0. To investigate the structural properties of the fibrillar
network, collagens and fibrillin-1 fibers were analyzed by
immunohistochemistry, second harmonic generation (SHG),
and autofluorescence (TPF) (Figure 5). Confocal microscopy
revealed that at day 6 type I, type III collagens, and fibrillin-1
were preserved by P1 treatment. Noteworthy, the associated
SHG signal, related to non-centrosymmetric organization of
the native collagen fibers, was increased upon P1 treatment,
showing that P1 improved the quality of collagen fiber
network. Merging immunohistochemistry and SGH signals
showed that these signals colocalized, indicating a higher
level of collagen fiber organization following P1 treatment
than in skin control. Similarly, immunohistochemistry analysis
of fibrillin-1 after P1 treatment revealed an improvement of
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Figure 3. Inhibition of matrix metalloproteinase-1 (MMP-1) and urokinase activities by peptides. (a) Inhibition of MMP-1 activity by P1, P4, and P5.
The curve represents the peptides’ dose–response (105, 104, or 103 M) relationship at time¼15 minutes. (b) Inhibition of collagenolysis by peptide (P1)
using skin tissue sections. Following collagen immunolabeling, skin specimens were analyzed with confocal microscopy and quantified by ImageJ analyses.
Collagens were identified in sections by staining with fluorescein isothiocyanate (green) and nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI; blue).
Bar¼10 mm. All experiments were repeated at least three times and a representative experiment is shown. (c) P1 cleavage by urokinase plasminogen
activator. The curve represents the P1 peptide dose–response (105, 104, or 103 M) relationship at time¼15 minutes. IC50 (peptide concentration leading
to 50% of enzyme inhibition) was determined as described in Materials and Methods.
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the fibrillar network, as observed by the length of the fibers
with respect to those in skin control. Furthermore, merging
immunohistochemistry and TFP (elastin autofluorescence
signal) signals revealed an improvement of the structural
elastic fiber network after treatment.
DISCUSSION
Matrikines are an ideal endogenous regenerative peptide
family, as they are produced naturally by the organism
following tissue insult (Maquart et al., 2005). Elastin-derived
peptides obtained from mammalian elastic tissues have been
found to act on many facets of wound healing (Antonicelli
et al., 2007, 2009). Elastin-derived peptides were often
incorporated into type I collagen scaffold and used as a
dermal equivalent, which improved pliability in patients
with burn injuries, for instance (Daamen et al., 2007). The
identification of the xGxxPG sequence within elastokine, as
the motif responsible for elastin-derived peptide biological
activity, was a major breakthrough (Brassart et al., 2001).
Although six amino acids were added to the C-terminal part of
the (VGVAPG)3 motif, the TFP (P1) still activated the S-Gal
receptor (also named elastin-binding protein) on the fibroblast
surface, demonstrating its membership to the elastokine
family. This TFP-(VGVAPG)3 part had the capacity to
stimulate type I collagen, type III collagen, and tropoelastin
expression by dermal fibroblasts both in in vitro culture and
ex vivo skin explants. TFP binding to S-Gal conducted the
activation of signaling pathways such as ERK1/2 and AKT. This
activation was in accordance with previous reports showing
that occupancy of S-Gal by elastokines triggered ERK
activation in fibroblasts, cardiomyocytes, or endothelial cells
(Duca et al., 2012; Hausenloy and Yellon, 2004; Duca et al.,
2005). The relationship between TFP stimulation and matrix
constituent upregulation was determined by activation
with a chemical inhibitor of PI3K/AKT and ERK1/2 that
resulted in drastic downregulation of TFP’s effects. Of note,
in our model, prolonged activation of the survival PI3K/AKT
pathway fits with the structural reorganization of the dermis in
the presence of TFP.
Increased MMP expression and activity is probably essential
during skin repair, but might be detrimental during skin aging
or in chronic skin pathology such as venous leg ulcers. In this
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Figure 4. Peptide 1 promotes matrix fiber regeneration in an ex vivo skin explant model. (a) Variation of matrix and matrix metalloproteinase-1 (MMP-1)
gene expression in ex vivo skin. Results are expressed as mean±SD of COL1A1, COL3A1, ELASTIN, and MMP-1 messenger RNA expression relative to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from three different experiments determined by quantitative real-time reverse-transcriptase–PCR on
days 0, 6, and 12. ***Pp0.001; **Pp0.01; *Pp0.5 versus day 0. (b) Variation of matrix protein expressions in an ex vivo skin explant model. Collagens or
elastin immunolabeling of skin was analyzed by confocal microscopy. Collagens and elastin were identified in sections by staining with fluorescein isothiocyanate
(green and cyan) and nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI; blue). Bar¼ 10 mm. All experiments were repeated at least three times
and a representative experiment with similar results is shown. Ctrl, control.
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Figure 5. Peptide 1 (P1) restores human dermal collagen and fibrillin-1 fiber array. Skin biopsies were cultured for 6 days. Following immunolabeling,
specimens were analyzed using confocal microscopy coupled with a CHAMELEON femtosecond titanium-sapphire laser. In purple: second harmonic generation
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setting, coupling elastokine domain with a sequence designed
to control MMP-1 activity was shown to be of interest to
reverse matrix protein degradation/expression balance. Within
the a1 (I), a2 (I), and a1 (III) chains of MMP-1, either a Gly775-
Ile776 or a Gly775-Leu776 bond is cleaved and the scissile bond
is followed by either alanine or leucine residue to constitute
an MMP-1 cleavage site (Netzel-Arnett et al., 1991). Thus, we
chose Gly–Ile–Leu as the tripeptide able to bind to MMP-1
subsites and to interfere with its activities. Indeed the GIL
sequence, either alone or associated to elastokine, inhibited
the activity of MMP-1 with an IC50 lesser than 10
 5
M. In
order to increase the protease inhibitory potential of our
molecules, a tetrapeptide RVRL designed to occupy the
plasmin active site was introduced as a linker between the
(VGVAPG)3 and GIL sequences. However, this sequence
was not cleaved by plasmin. This peptidase contains kringle
domains displaying strong affinity for hydrophobic mole-
cules such as oleic acid (Huet et al., 2004). Therefore, the
(VGVAPG)3 sequence might interact with these domains,
preventing TFP from occupying plasmin subsites. Neverthe-
less, uPA containing only one kringle proved to hydrolyze the
full-length TFP and to act as a competitive substrate. Thus, the
presence of such a linker might interfere with the proteolytic
cascade, leading to ProMMP-1 activation, or could potentiate
the anchoring of the peptide to uPA associated with the cell
plasma membrane, hence preventing pericellular collageno-
lysis or increasing elastokine presentation to S-Gal. Indeed, the
influence on matrix synthesis was potentiated by the presence
of the RVRLGIL sequence. Then, collectively the validity of
our peptidic approach was substantiated by the skin explant
model, which reproduced the ex vivo degenerative changes
observed in skin aging or ulcers. Indeed, TFP treatment for up
to 12 days maintained the initial collagen network integrity by
acting at the level of both collagen synthesis and degradation.
Besides, it might be recognized that potent MMP-1 inhibitors
could be linked to elastokines. However, MMP-1 plays a
crucial role in the migration of keratinocytes during wound
healing (Dumin et al., 2001), and strong or irreversible
inhibition of this enzyme might direct towards a fibrotic
feature. Subsequently, the mild MMP-1 inhibition associated
with the induced matrix molecules’ overexpression upon TFP
stimulation argues for the formation of a non-fibrotic matrix
architecture, and therefore highlights the advantages of the use
of TFP over classical MMP inhibitors.
Fibrosis results from excessive extracellular matrix deposi-
tion in the course of chronic inflammation and wound
healing, and can generate pathogenic processes. TFP proved
to exhibit a higher potentiality to enhance type III collagen
expression compared with type I collagen. Since early wounds
occurring during fetal life heal more efficiently than adult
wounds, it has been suggested that high amounts of type III
collagen in fetal skin could be related to non-scarring repair
(Ferguson and O’Kane, 2004). Of note, type I collagen is the
predominant collagen in normal human skin and exceeds type
III collagen by a ratio of 4:1, whereas this ratio decreases
to 2:1 in wound healing, due to an early increase in the
deposition of type III collagen (Peacock, 1984). Thus, early
deposition of type III collagen in wounds appears as a crucial
step for the evolution of the healing process. Also, diminished
type III collagen promotes myofibroblast differentiation and
increases scar deposition in cutaneous wound healing
(Volk et al., 2011). Of interest, the increase of matrix
protein expression by TFP was transient, as observed in the
ex vivo model, after 12 days of TFP treatment. Collectively,
these data excluded the possibility that TFP treatment could
lead to dermal fibrosis (Elliott and Hamilton, 2011). Moreover,
we demonstrated by SHG and TPF microscopy that TFP
improved the layout of the collagen and elastin fiber
network. More organized and structured fibers, demonstrated
by the use of the established techniques SHG and TFP
(Zhuo et al., 2012), suggest that TFP can properly rebuild
the extracellular matrix of human dermis (Chen et al., 2011)
and can be considered as a skin remodeling and regenerative
molecule.
MATERIALS AND METHODS
Design of TFP
TFP was constituted of an elastokine motif (VGVAPG)3 (Brassart et al.,
2001; Antonicelli et al., 2007) associated to a linker quadripeptide
RVRL and to a tripeptide GIL. The (VGVAPG)3 sequence was
chosen to interact with S-Gal; RVRL sequence for the ability of an
individual amino acid to recognize subsites from proteases of the
plasminogen system; and GIL sequence to occupy P1, P
0
1, and P
0
2
of MMP-1 (Rawlings et al., 2012). To validate TFP’s functionality,
its properties were compared with those corresponding to part
of its structures: P1 or TFP¼ (VGVAPG)3-RVRL-GIL (MW:
2468.88 g mol 1); P2¼ (VGVAPG)3-RVRL (MW: 2131.47 g mol 1);
P3¼ (VGVAPG)3 (MW: 1459.69 g mol 1); P4¼RVRL-GIL (MW:
1019.2 g mol 1); P5¼GIL (MW: 347.39 g mol 1).
Peptide synthesis
Peptides were obtained from Proteogenix Company (Grenoble,
France). Briefly, they were synthesized following the fluorenyl-
methoxycarbonyl/tert-butyl strategy, and purified by reverse-phase
high pressure liquid chromatography using a Kromasil C18 Jupiter
(Bio-Rad, Marnes-la-coquette, France) column (250 21.2 mm) using
a linear gradient (0–100%) of 0.1% TFA/acetonitrile in 0.1% TFA/
water. Peptide purity was assessed by reverse-phase high pressure
liquid chromatography (Beckman System Gold 126, Villepinte,
France) using a Chromolith C18 Jupiter (VWR, Fontenay-sous-bois,
France) column (50 4.6 mm), applying a linear gradient (0.1% TFA/
acetonitrile in 0.1% TFA/water from 0 to 100% over 3.5 minutes).
Their purity exceeded 99% and they were further characterized
by mass spectrometry (Waters Micromass Quattro Micro, Milford,
MA, OPTON ESI source).
Fibroblast cultures and treatment
Primary HDFs were obtained from abdominal biopsies (Plastic
Surgery Department, Reims Clinic), with the written informed consent
of donors and approval by the local ethical committee according to
the principles of the Declaration of Helsinki. HDFs were cultured as
previously described (Attia et al., 2008). Cells (5–9th passages) were
seeded in plastic wells. Before stimulation, cells were serum starved
for 18 hours and then incubated up to 24 hours in serum-free DMEM
with or without peptides (100mg ml 1). The pharmacological
inhibitors U0126 (10mM), LY294002 (20mM), and lactose (2 mM)
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were introduced 1 hour before stimulation. All experiments were
performed at least three times.
Skin biopsies and ex vivo culture conditions
Skin biopsies were cut into small pieces (0.5 cm2) and cultured
according to the method originally described by Trowell and
Companjen (Trowell, 1959; Companjen et al., 2001). Biopsy
sample was inserted in a Transwell filter (pore size 0.75mm;
Dutscher, Brumath, France) punched (2-mm hole) and placed in a
culture plate containing 1 ml medium with or without peptide. The
epidermis was held facing upwards at the liquid–air interface and
the dermis immersed into the culture medium. The explants were
incubated at 37 1C in the presence of 5% CO2 in a humidified
atmosphere and cultured in DMEM supplemented with 10% fetal
calf serum (Dutscher), 1% non-essential amino acids (Sigma,
St Quentin Fallavier, France), penicillin (100 U ml 1), and streptomycin
(100mg ml 1). Skin explants were treated with peptides (100mg ml 1)
in DMEM supplemented with 10% fetal calf serum, 1% non-essential
amino acids, and antibiotics. The medium containing, or not, peptides
was changed every 2 days. Biopsies were analyzed after 3, 6, and 12
days. All experiments were performed at least three times.
Western blot
Fibroblasts (180,000 cells cm 2), 80% confluence, were washed
twice in ice-cold phosphate-buffered saline and scrapped in lysis
buffer (50 mM Tris-HCl, pH 7.5, 1% NP-40, 150 mM NaCl, 1 mM
EGTA, 1 mM NaF, 1 mM Na3VO4, and protease inhibitor cocktail).
Insoluble material was removed by centrifugation (14,000 g, 30 min-
utes, 4 1C). Protein concentrations were determined by bicinchoninic
acid protein assay (Interchim, Montluc¸on, France). Equal amounts of
protein were heated for 5 minutes at 100 1C in Laemmli sample
buffer, resolved by SDS-PAGE under reducing conditions, and
transferred to a polyvinylidene difluoride membrane (Merk-Millipore,
Nottingham, UK). After saturation (1 hour, Tris buffer saline–0.1%
Tween 20, 10% non-fat dry milk), membranes were incubated
overnight at 4 1C with anti-type I collagen, anti-type III collagen,
anti-elastin, anti-actin, anti-P-ERK, anti-ERK, anti-P-AKT, anti-AKT
(sc-8783, H-300, sc-17581, sc-1616, sc-377400, sc-292838,
sc-1619, sc-135650, respectively, Santa-Cruz Biotechnology,
Heidelberg, Germany), anti-MMP-1, or anti-MMP-3 (IM35, IM36,
respectively, by Merk-Millipore). Then, the membranes were rinsed
with TBS-T and incubated for 1 hour with secondary antibodies
(horseradish peroxidase (HRP)-conjugated goat anti-rabbit or anti-
mouse antibody; Santa Cruz Biotechnology). Protein bands were
revealed using a detection kit (ECL Detection Systems, Amersham,
France) and quantified using the ImageJ program system (National
Institutes of Health, Bethesda, MD).
RNA extraction and real-time RT–PCR
Total RNA was extracted using the Trizol (Fisher Scientific, Illkirch,
France) method and quantified on a spectrophotometer (Nanovue
Plus, Agilent, Les Ulis, France). Then, 1mg of DNase I-treated RNA
was reverse transcribed into complementary DNA in the presence of
random hexamers (Applied Biosystems, Courtaboeuf, France) and
moloney murine leukemia virus reverse transcriptase, in a final
volume of 20ml. Then, 5ml of diluted complementary DNA (1/100)
was mixed with forward and reverse primers (500, 500, 600, 500 and
200 nM, for COL1A1 (NM_000088.3), COL3A1 (NM_000090.3),
ELASTIN (NM_000501.2), MMP-1 (NM_002421.3), and GAPDH
(NM_002046.4), respectively) and 2X SYBR Green PCR Master Mix
(Fermentas, Fisher Scientific) in a final volume of 20ml. Cycling
parameters were as follows: 1 cycle at 95 1C for 10 minutes and
42-segment cycles for amplification (95 1C for 10 seconds and 60 1C
for 1 minute). Serial dilutions of complementary DNA were also
amplified to establish a standard curve. All samples were amplified in
triplicate and all messages showed an equal efficiency of amplifica-
tion. The relative COL1A1, COL3A1, ELASTIN, MMP-1, and GAPDH
expression levels were calculated with the 2DDCT method (Livak and
Schmittgen, 2001).
Confocal microscopy (immunofluorescence, SHG, and TPF)
Samples of human skin were frozen in liquid nitrogen. Sections (5mm
thick) were then cut with a cryostat (Cryocut 1800, Leica, Nanterre,
France) fixed for 15 minutes in 4% paraformaldehyde. After phos-
phate-buffered saline wash, the skin sections were incubated in
phosphate-buffered saline 1 with 30% BSA (Sigma) for 30 minutes
at room temperature, then treated overnight (4 1C) with anti-type I
collagen, anti-type III collagen, anti-elastin (the same antibodies as
used in western blots), and anti-fibrillin 1 (MAB2502, Merk-Milli-
pore). After rinsing, they were incubated for 2 hours with the
fluorescent secondary antibody, a fluorescein isothiocyanate-conju-
gated goat anti-rabbit or anti-mouse IgG antibody (Tebu-bio SA, Le
Perray-en-Yvelines, France). After mounting with DAPI-containing
medium (40,6-diamidino-2-phenylindole dilactate, UltraCruz Mounting
Medium, Santa Cruz Biotechnology), samples’ images were obtained
with a confocal microscope (LSM 710-NLO, Zeiss Microsystems,
Gennevilliers, France) coupled with CHAMELEON femtosecond
Titanium-Sapphire Laser (Coherent, Santa Clara, CA). Backward
SHG signal and elastin autofluorescence were simultaneously
collected using 860 nm excitation wavelength with 420–440 band-
pass filters and 560–700 nm longpass emission filters, respectively
(Ko¨nig et al., 2005; Pena et al., 2007; Fritze et al., 2010). Fluorescein
isothiocyanate (488 nm excitation, 500–560 nm bandpass emission
filters) and DAPI (740 nm excitation with CHAMELON laser, 420–
480 nm bandpass emission filters) signals were collected sequentially.
All acquisition settings were constant between specimens.
Determination of collagenase-1 activity (MMP-1)
Synthetic substrate. The influence of peptides (P1 and P5) on
APMA-activated recombinant ProMMP-1 was determined using
DNP-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH2 as substrate
(Calbiochem, Merck-Millipore, Nottingham, UK) (Ledour et al.,
2008). MMP-1 (80 ng ml 1) was incubated in 0.1 M Tris-test buffer,
pH 7.8, containing substrate (10mM), in the presence or absence of
peptide (10 5, 10 4, or 10 3 M). The rate of substrate cleavage was
measured using the Perkin-Elmer LS50B spectrofluorometer with
excitation and emission wavelengths of 360 and 465 nm, respec-
tively. MMP-1 activity was monitored continuously for 35 minutes. IC50
was determined from dose–response curves at 15 minutes.
Skin tissue section. The influence of TFP on MMP-1 activity was
also determined using skin tissue section. Collagenase-1 (MMP-1;
80 ng ml 1) was disposed on 5mm skin section in the presence or
absence of TFP (P1) (100mg ml 1). Four hours after treatment,
sections were fixed in 4% paraformaldehyde and immunolabeled
for type I collagen and type III collagen.
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Cleavage of TFP by plasmin and urokinase (uPA)
Plasmin (1.5 10 5 M) was incubated in 0.1 M Tris buffer in the
presence of TFP (P1) (0.4 mM). After 1 hour, the plasmin was removed
on ultrafiltration spin columns (Vivaspin 6, Sartorius, Goettingen,
Germany) and the hydrolyzed fraction was analyzed by high-
performance liquid chromatography (Chromolith C18 Jupiter,
50 4.6 mm). Similarly, the cleavage of TFP (P1) (0.4 mM) by uPA
(1.9 10 5M) was assessed.
Determination of plasmin and uPA activities
The influence of P1 (10 5, 10 4 or 10 3 M) on 1.5 10 5 M
plasmin and 1.9 10 5 M uPA was determined using 0.3 mM
D-Val-Leu-Lysþ NHPh NO2 (S2251, Chromogenix, West Chester,
OH) and 0.3 mM D-Glu-Gly ArgþNHPhNO2 (S2444, Calbiochem),
respectively (Huet et al., 2002).
Plasmin or uPA was incubated in 0.1 M Tris buffer, pH 7.8,
containing 0.3 mM of S-2251 or S-2444, respectively, in the presence
or absence of peptide. The rate of substrate hydrolysis was quantified
at 405 nm, at 5-minute intervals, using the Perkin-Elmer LS50B
spectrofluorometer. The dose–response relationship was determined
at t¼ 15 minutes and IC50 (peptide concentration leading to 50%
inhibition) was evaluated
Statistical analysis
All experiments were repeated at least three times and representative
experiments are shown. Data are presented as means±SD. Statistical
significance was determined by Mann–Whitney test. Differences were
considered to be statistically significant at *Po0.05; **Po0.01; and
***Po0.001.
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